Sagimet updates Q2 2026 results with new investor presentation filing
The company reiterated its $257.6 million cash position and confirmed plans for a Phase 3 acne trial of denifanstat in the second half of 2026, alongside a new investor slide deck.
Sagimet Biosciences reported financial results for the quarter ended June 30, 2026, on August 11, 2026, and filed an accompanying 8-K that also discloses an updated investor presentation. On August 11, 2026, the company updated information reflected in a slide presentation, which representatives plan to use in various meetings with investors from time to time.1
Cash, cash equivalents and marketable securities as of June 30, 2026, were $257.6 million.1 The company said this level of cash is expected to fund current operations through 2028, including through data readout of denifanstat Phase 3 trial in moderate to severe acne.1
In April 2026, Sagimet announced a strategic decision to advance denifanstat in moderate to severe acne for the U.S., prioritizing its dermatology programs in its capital allocation.1 That same month, the company completed an underwritten equity financing resulting in $175.0 million of gross proceeds, before deducting underwriting discounts and commissions and other offering expenses.1
On the pipeline, a first-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 is ongoing.1 Sagimet said it intends to advance denifanstat into a registrational Phase 3 clinical trial in moderate to severe acne patients for the U.S. in the second half of 2026.1 It also said upon completion of the Phase 1 clinical trial of TVB-3567, subject to consultation with regulatory authorities, Sagimet plans to initiate a Phase 2 clinical trial with TVB-3567 in moderate to severe acne patients before the end of 2026.1
On expenses, research and development expense for the three and six months ended June 30, 2026, was $11.5 million and $18.5 million, respectively, compared to $7.2 million and $22.6 million for the three and six months ended June 30, 2025.1 General and administrative expense for the three and six months ended June 30, 2026, was $4.3 million and $9.0 million, respectively, compared to $4.7 million and $9.2 million for the same periods in 2025.1 Net loss for the three and six months ended June 30, 2026, was $14.0 million and $24.6 million, respectively, compared to $10.4 million and $28.6 million for the three and six months ended June 30, 2025.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.